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Abstract 
Objective 
Two versions of a patient-based disease activity score (PDAS) 1 and 2 (with and 
without ESR) have been developed and validated in rheumatoid arthritis (RA). 
The objective of this study is to define PDAS1 and PDAS2 based criteria for 
remission, low, moderate and high disease activity and responses to treatment. 
 
Method 
Using receiver operator characteristic (ROC) curves, the optimal thresholds for 
PDAS1 and PDAS2 that correspond to validated assessor-based Disease Activity 
Score (DAS28) and Clinical Disease Activity Index (CDAI) disease statuses were 
determined.  Data from RA patients initiated on disease modifying drugs were 
used to determine optimal thresholds for PDAS1 and PDAS2 that corresponded 
to EULAR good and moderate responses.  Agreement with DAS28, CDAI and 
EULAR response criteria were assessed by Cohen’s kappa ȋκȌ statistics. 
 
Results 
Threshold for PDAS1 and PDAS2 demonstrated fair to moderate agreement with 
DAS28 (κ = 0.ͶͶ [95% confidence interval: 0.40-0.50] and 0.31 [95% CI: 0.25-
0.38]) and CDAI (κ = 0.27 [95% CI: 0.22-0.33] and 0.42 [95% CI: 0.35-0.49]) 
disease statuses respectively, which were similar to agreement between DAS28 
and CDAI (κ = 0.54 [95% CI: 0.46-0.61]) within this group. Agreement between 
EULAR good and moderate response with PDAS1 and PDAS2 were κ = 0.Ͷ͸ (95% 
CI:  0.27-0.64) and 0.38 (95% CI: 0.20-0.56), respectively. 
 
Conclusion 
Thresholds for disease activity statuses and response to treatment for PDAS1 
and PDAS2 have been established. They have comparable agreement to assessor-
based criteria. 
 
 
(Abstract word count: 232) 
 
 
 
 
Key Messages 
1. We established thresholds for disease activities and response criteria for 
Patient-based Disease Activity Scores.  
2. They have moderate agreement with Disease Activity Score 28 and Clinical 
Disease Activity Index. 
3. They would be useful for rheumatoid arthritis patients self-monitoring to 
facilitate treat-to-target strategy.  
Introduction 
Rheumatoid Arthritis (RA) affects 0.5-1% of the population [1]. Inflammation 
leads to joint damage resulting in pain, swelling and disability [2]. Sustained 
suppression of the inflammation has been shown to be important in preventing 
joint damage in RA [3]. Therefore, treat-to-target towards remission or low 
disease activity is the current standard of care recommended by 
National Institute for Health and Clinical Excellence [4], European League 
Against Rheumatism [5] and American College of Rheumatology [6]. Monitoring 
disease activity regularly is important in achieving this goal. Current 
recommendation is to assess patients 1-3 monthly using measures such as 
Disease Activity Score28 (DAS28)[7], Simplified Disease Activity Index (SDAI)[8] 
or Clinical Disease Activity Index (CDAI)[9] all of which require patients 
attending hospital to be assessed by a healthcare professional. Patients with RA 
should self-monitor disease activity at home, akin to diabetic patients self-
monitoring blood sugar so that they can seek medical advice promptly when 
disease is active.  
 
Patient Disease Activity Score (PDAS) is a validated patient self-assessed score of 
disease activity [10], which does not require any prior training. The preliminary 
items of the PDAS were selected based on a systematic review of disease activity 
self-assessment items. It included all the patient-reported outcome domains 
from the Outcome Measure in Rheumatology (OMERACT) core data set i.e. pain, 
patient global (PGA), Health Assessment Questionnaire (HAQ). It also added 
early morning stiffness (EMS), fatigue, patient self-assessed tender count (TJC) 
and patient self assessed swollen joint count (SJC)[11]. Two versions of the PDAS 
were developed and validated: PDAS with the ESR (PDAS1= 0.019 x (PGA out of 
100) + 0.842 x ln(ESR + 2) + 0.432 x ln(patient 50 TJC + 2) + 0.271 x (HAQ) or 
without ESR (PDAS2 
 = 2.667 + 0.021 x (PGA out of 100) + 0.483 x (HAQ) + 0.033 x (patient 28 SJC) + 
0.002 x (EMS in minutes)). 
Components of PDAS1 and 2 were selected based on best statistical modelling 
against gold standard at the time, Disease Activity Score (DAS28), therefore 
correlate highly with DAS28 but different components were selected for PDAS1 
and 2. Laboratory tests were removed from PDAS2 intentionally, so as to develop 
an instrument that assess disease activity without the need for a blood test. 
Internal consistency, test-retest reliability, criterion and construct validity were 
demonstrated during validation. Moreover, the sensitivity of change of PDAS1 
and PDAS2 is also similar to DAS28. Interestingly, for patients with RA and 
concomitant fibromyalgia, tender joint count and pain score are often higher 
than patients without fibromyalgia[12]. However, swollen joint count including 
patient self-assessed swollen joint count is not affected. Consequently for PDAS2, 
the scoring is more weighted on self-assessed swollen joint count than tender 
joint count, which differs from DAS28. 
 
Like DAS28, PDAS1 and PDAS2 are continuous status measures. However, 
thresholds for defining response to treatment and remission have not yet been 
established.  The objective of this study is to define thresholds, based on PDAS1 
and PDAS2, for disease status: remission, low, moderate and high disease 
activities and European League Against Rheumatism (EULAR) good and 
moderate responses[13] to treatment. 
 
Method 
Data from 299 RA patients, originally used to develop and validate PDAS[10] 
were used for this study. Briefly, they were patients who attended Rheumatology 
outpatients clinics who met the 1987 American College of Rheumatology criteria 
for RA[14]. In addition, data from 56 patients who had started disease-modifying 
anti-rheumatic drugs (DMARDs) (50 patients) or biologic agents (6 patients) and 
were seen 6 months apart were used to determine optimal thresholds for PDAS1 
and PDAS2 corresponding to EULAR responses criteria. Conventional disease 
outcome assessments were also performed, including tender and swollen joint 
counts (28 joints), and were used to calculate the DAS28 and Clinical Disease 
Activity Index (CDAI). 
 
The study was approved by the South Thames Multicentre Research Ethics 
Committee and all patients gave written informed consent. 
 
Determining the optimal thresholds 
Receiver operator characteristic (ROC) curves were plotted to determine the 
optimal thresholds for PDAS1 and PDAS2 that corresponded to validated DAS28 
and CDAI criteria for remission, mild, moderate and high disease activity states. 
Optimal thresholds were obtained by maximising the average of sensitivity and 
specificity. Agreement with DAS28 and CDAI thresholds and EULAR response 
criteria were assessed with Cohen’s kappa ȋκȌ statistics. Intraclass correlation 
coefficient (ICC) was used to assess agreement between PDAS1 and PDAS2 with 
DAS28 and CDAI as continuous variables. Kappa value ranging from 0.21 to 0.40 
is conventionally taken as fair agreement, 0.41 to 0.60 moderate, and 0.61-0.80 
substantial[15]. The number of patients scoring extreme discordance was also 
calculated, i.e. scoring remission in one index and high activity in another, or 
good response in one and non-response in another. 
 
 
  
Results 
Patients 
299 RA patients with established RA were included in this analysis. 225 (75%) 
were female and 74 (25%) were male.  Mean age was 60 years (standard 
deviation 13 years) with average disease duration of 9 years (SD 11 years). Most 
of the patients 81% were rheumatoid factor positive. The mean age of the 56 
patients who were started on a new treatment, was 55 years (SD 14 years). The 
mean disease duration was 8 years (SD 10 years). Eighty-eight percent of the 
patients were female and 63% were rheumatoid factor positive. 
 
Thresholds for remission, low, moderate and high disease activity for 
PDAS1 and PDAS2 
The corresponding thresholds for differentiating DAS28 remission, low, 
moderate and high disease activity states for PDAS1 were 3.5, 4.5 and 4.8; and 
3.8, 4.6 and 5.0 for PDAS2 respectively. Scatter plots of PDAS1&2 to DAS28 and 
CDAI are in Figure 1 and Figure 2 respectively. Areas under curve (AUC) for all 
the above ROC curves were from 0.89 to 0.95 (all p<0.001). Sensitivities for 
PDAS1&2 to DAS28 were respectively: remission versus not in remission (92%, 
90%), remission and low versus moderate and high disease activity (99%, 89%), 
remission, low or moderate activity versus high activity (95%, 79%). 
Correspondingly, specificities for PDAS1&2 to DAS28 for these states were 
respectively: 89%, 71%; 61%, 69%; 74%, 82%.  
 
Similarly for CDAI, AUC for all ROC curves were from 0.86 to 0.93 (all p<0.001). 
Sensitivities for PDAS1&2 to CDAI were respectively: remission versus not in 
remission (70%, 84%), remission or low disease activity versus moderate or 
high disease activity (77%, 88%), remission, low or moderate activity versus 
high activity (88%, 79%). Correspondingly, specificities for PDAS1&2 in these 
states were respectively: 91%, 95%; 85%, 80%; 69%, 91%. 
 
These thresholds demonstrated fair to moderate agreement with DAS28 disease 
activity categories was observed: κ = 0.ͶͶ (95% CI: 0.40-0.50) for PDAS1 and 
0.31 (95% CI: 0.25-0.38) for PDAS2. ICC between DAS28 and PDAS1 was 0.78 
(95% CI: 0.72-0.82) and PDAS2 was 0.65 (95% CI: 0.57-0.71). Corresponding 
agreements with CDAI were κ = 0.2͹ (95% CI: 0.22-0.33) for PDAS1 and 0.42 
(95% CI: 0.35-0.49) for PDAS2. ICC between CDAI and PDAS1 was 0.65 (95% CI: 
0.58-0.71) and PDAS2 0.68 (95% CI: 0.62-0.74). These agreements were similar 
to those of CDAI and DAS28 within the same group of patients, with κ = 0.ͷͶ 
(95% CI: 0.46-0.61) and ICC 0.81 (95% CI: 0.77-0.85). Extreme discordance with 
DAS28 was uncommon: none in PDAS1 and only two patients (0.7%) in PDAS2. 
Extreme discordance with CDAI was also uncommon: nine patients (3%) in 
PDAS1, and one patient (0.3%) in PDAS2. There was no extreme discordance 
between DAS28 and CDAI. 
 
Definitions for Good, Moderate and Non-response 
PDAS1 and PDAS2 based definitions for good, moderate and non-response are 
summarised in Table 1. Any patient with a reduction of less than 0.4 or 0.3 of 
PDAS1 and PDAS2 respectively were non-responders. A good responder was 
defined by a reduction in PDAS1 score by at least 0.8 and an end PDAS1 score of 
<4.5. For PDAS2, the corresponding values were a reduction of >1.2 and an end 
PDAS2 score of <4.6.  They aligned well with EULAR response criteria with AUC 
under ROC ranged from 0.88 to 0.93 (all p<0.001). Sensitivities for PDAS1&2 to 
DAS28 responses were respectively: non-response versus moderate or good 
response (75%, 72%), and no or moderate response versus good response 
(100%, 68%). Corresponding specificities for PDAS1&2 were respectively: 94%, 
89%; 77%, 93%. 
 
Agreement of EULAR response criteria and PDAS1&2 were moderate:  κ = 0.46 
(95% CI: 0.27-0.64) and 0.38 (95% CI: 0.20-0.56) respectively, and ICC = 0.71 
(95% CI: 0.56-0.82) and 0.49 (95% CI: 0.26-0.67) respectively. The agreement of 
DAS28 and CDAI within this patient group was also moderate (κ = 0.55, 95% CI 
0.36-0.73). Extreme discordance with DAS28 response was uncommon: one 
patient (2%) in PDAS1 and four patients (7%) in PDAS2. On the other hand, 
extreme discordance with CDAI was less uncommon: eight patients (14%) in 
PDAS1 and four patients (7%) in PDAS2. Notwithstanding, extreme discordance 
between DAS28 and CDAI responses occurred in 3 patients (5%). 
 
  
Discussion 
In RA, there are many validated tools to assess disease activity, which are 
extensively used in clinical trials and routine daily practice. They are 
fundamental to delivering the current standard of care: treat-to-target. All these 
tools required an assessor conducting an examination to determine the number 
of tender and swollen joints. Therefore, patients need to attend clinics for these 
assessments to be conducted. Many patients complain of disease flare in 
between clinic visits. The PDAS1&2 scores were developed to enable patients to 
self-assess disease activity.  They have been validated and shown to correlate 
well with DAS28 and CDAI, are sensitive to change [10].  
 
Here we use standard statistical modelling to define thresholds for defining high, 
moderate, low disease activity and remission as well as good, moderate and non-
response for PDAS1 and PDAS2. They have comparable agreement to current 
gold standard assessor based criteria, DAS28 and CDAI. Indeed, the degree of 
agreement was comparable to that of DAS28 and CDAI within this patient group 
(κ = 0.55, 95% CI: 0.36-0.73), which was similar to that in CORRONA study (κ = 
0.57)[16] and in original CDAI derivation study (κ = 0.52)[17].  Although PDAS2 
appeared to have comparatively lesser agreement with DAS28 than PDAS1 
(p<0.05, non-overlapping 95% CI) by kappa statistics and ICC, this not surprising 
ESR was a component of DAS28 and PDAS1. Indeed, PDAS2 did have better 
agreement with CDAI than PDAS1 by kappa statistics, but not ICC. PDAS2 
(without ESR) has the clinical advantage of obviating the need for blood test. 
 
Gross mis-classification of disease activities or response criteria was uncommon, 
as evident by the low proportion of extreme discordance (0-3% for activities and 
2-14% for response), given that even 5% of patients would have extreme 
discordance between DAS28 and CDAI responses. The moderate disease activity 
interval for PDAS is relatively short, and many patients classified as moderate 
disease by DAS28 are in high disease activity by PDAS. However, in terms of 
treat-to-target strategy, the difference is insignificant, as these patients should be 
treated to achieve remission or low disease activity status. The major difference 
in DAS28 and PDAS is in the assessment of joint count. First, patients score 
higher on tender joint count than assessor [20,21]. Second, interobserver 
variability in assessor-based tender joint and swollen joint count is very high 
with coefficient of variation of up to 204% [22]. The narrow range of PDAS is 
likely to result from reduced interobserver variability. In clinical trials, protocols 
often stipulate joint count assessment be performed by one assessor. In clinical 
practice, this is not feasible, joint counts are often carried out by different 
assessors. 
The development of PDAS is not intended to replace assessor based disease 
activity tools, rather the aim is to develop a complimentary tool that facilitates 
treat-to-target by allowing patients to monitor disease at home. PDAS1 and 2 are 
being used in the Canadian Early Arthritis Cohort study and the UK Health 
Technology Assessment funded Reducing Arthritis Fatigue Trial. 
 
Defining self-assessed disease activity states may be useful to prompt patients to 
seek medical advice when RA is active. However, further studies will be needed 
to test the clinical effectiveness of PDAS in implementing treat-to-target strategy. 
(Body text word count 1986)  
Table 1: Definitions of good, moderate and non-response based on Patient 
based Disease Activity Score (PDAS) 1 and 2. 
 
 
 
 
 
PDAS1 response criteria: Improvement 
Final score >0.8 0.4 - 0.8 ≤0.4 
PDAS1≤4.5 Good Moderate No 
4.5 < PDAS1≤ 4.8 Moderate Moderate No 
PDAS1 > 4.8 Moderate No No 
PDAS2 response criteria: Improvement 
Final score >1.2 0.3 - 1.2 ≤0.3 
PDAS2≤4.6 Good Moderate No 
4.6 < PDAS1≤ 5.0 Moderate Moderate No 
PDAS1 > 5.0 Moderate No No 
Legends for Figures: 
 
Figure 1: (a) Scatter plots of PDAS1 to DAS28. Circles are patients in PDAS1 
remission.  Triangles are patients in PDAS1 low disease activity. Squares are 
patients in PDAS1 moderate disease activity. Pentagons are patients in PDAS1 
high disease activity. (b) Scatter plots of PDAS2 to DAS28. Circles are patients in 
PDAS2 remission.  Triangles are patients in PDAS2 low disease activity. Squares 
are patients in PDAS2 moderate disease activity. Pentagons are patients in 
PDAS2 high disease activity. 
 
Figure 2: (a) Scatter plots of PDAS1 to CDAI. Circles are patients in PDAS1 
remission.  Triangles are patients in PDAS1 low disease activity. Squares are 
patients in PDAS1 moderate disease activity. Pentagons are patients in PDAS1 
high disease activity. (b) Scatter plots of PDAS2 to CDAI. Circles are patients in 
PDAS2 remission.  Triangles are patients in PDAS2 low disease activity. Squares 
are patients in PDAS2 moderate disease activity. Pentagons are patients in 
PDAS2 high disease activity. 
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